biostudies-literatureSaunders UNIDDK NIH HHSNIAID NIH HHS1718-1729https://www.ebi.ac.uk/biostudies/studies/S-EPMC8128940biostudies-literatureUnknown105(8)<h4>Background</h4>Human cytomegalovirus (CMV) infection is associated with renal allograft dysfunction and loss, particularly in combination with acute rejection. Emerging literature suggests that non-HLA antibodies may contribute to antibody-mediated rejection, but pathogen-induced antibodies have not been investigated in this context. This study examines the presence of CMV-induced antibodies in murine CMV (MCMV)-infected renal allografts during acute rejection.<h4>Methods</h4>Intragraft immunoglobulin G (IgG) and complement C3 immunostaining were compared among allogeneic MCMV D-/R-, D+/R-, and D+/R+ renal transplants. Intragraft antibody deposition was examined in B cell-deficient recipients treated with MCMV immune sera. Antibody binding and complement-dependent cytotoxicity (CDC) ofTransplantationMurine Cytomegalovirus-induced Complement-fixing Antibodies Deposit in Murine Renal Allografts During Acute Rejection.PMC8128940R24 DK064400R01 AI101138P30 DK079337Saunders UKaptsan IZeng QCianciolo RBoddeda SRChen BLi MVelazquez VGuo LGhere JSchoeb TRDhital RMaher SShimamura MfalseMurine Cytomegalovirus-induced Complement-fixing Antibodies Deposit in Murine Renal Allografts During Acute Rejection.<h4>Background</h4>Human cytomegalovirus (CMV) infection is associated with renal allograft dysfunction and loss, particularly in combination with acute rejection. Emerging literature suggests that non-HLA antibodies may contribute to antibody-mediated rejection, but pathogen-induced antibodies have not been investigated in this context. This study examines the presence of CMV-induced antibodies in murine CMV (MCMV)-infected renal allografts during acute rejection.<h4>Methods</h4>Intragraft immunoglobulin G (IgG) and complement C3 immunostaining were compared among allogeneic MCMV D-/R-, D+/R-, and D+/R+ renal transplants. Intragraft antibody deposition was examined in B cell-deficient recipients treated with MCMV immune sera. Antibody binding and complement-dependent cytotoxicity (CDC) of2021-01-01T00:00:00Z2021 Aug2025-04-04T21:24:41.996Z2025-04-04T21:24:41.996ZS-EPMC81289403321453510.1097/TP.000000000000354810.1097/tp.0000000000003548